EpiVax, Inc. - Informatics and Immunology
  • Our Company
    • Company Overview
    • Corporate Responsibility
    • Mission, Vision & Values
    • Team
    • Careers
    • Contact Us
  • Pipeline
    • Pipeline Overview
    • BioDefense Vaccines
    • Tregitope: Immunomodulation Power Tool
    • Deimmunization Projects
  • Vaccine Services
    • Vaccine Services
    • iVAX: Web-based Vaccine Design
    • PreVAX Analysis
    • EpiCC
  • Immunogenicity Assessment
    • Immunogenicity Assessment Overview
    • ISPRI Web-based Immunogenicity Assessment
    • PreDeFT Analysis
    • High Throughput Immunogenicity Analysis
    • PANDA Screening
    • ISPRI for Host Cell Proteins
    • Deimmunization
    • Trusted Expert Advice (TEA) Consulting Services
  • Lab Services
    • Lab Services Overview
    • HLA Binding Assays
    • T Cell Assays
  • Press Room
    • Press Room
    • Events
      • Webinars
    • Publication & Poster Search
    • Client Testimonials
    • Thinking Out Loud (Blog)
    • Recipes For Success (Podcast)
  • Contact Us
Select Page
Promiscuous T Cell Binding Epitopes in Two Osteoporosis Medications Lead to Different Immunogenicity Profiles: A Tale of Two Peptides

Promiscuous T Cell Binding Epitopes in Two Osteoporosis Medications Lead to Different Immunogenicity Profiles: A Tale of Two Peptides

by Corey Iacono | Mar 14, 2023

Promiscuous T Cell Binding Epitopes in Two Osteoporosis Medications Lead to Different Immunogenicity Profiles: A Tale of Two Peptides  
A SARS-CoV-2 T cell epitope homologous to a validated human Treg epitope (Tregitope) suppresses CD4 and CD8 T cell memory responses

A SARS-CoV-2 T cell epitope homologous to a validated human Treg epitope (Tregitope) suppresses CD4 and CD8 T cell memory responses

by Corey Iacono | Aug 29, 2022

A SARS-CoV-2 T cell epitope homologous to a validated human Treg epitope (Tregitope) suppresses CD4 and CD8 T cell memory responses Shah Md. Shahjahan Miah, Andres Gutierrez, Sandra Lelias, Christine M. Boyle, Lenny Moise, Anne S. De Groot EpiVax Inc, Providence, RI...
Novel H7N9 influenza immunogen design enhances mobilization of seasonal influenza T cell memory in H3N2 pre-immune mice

Novel H7N9 influenza immunogen design enhances mobilization of seasonal influenza T cell memory in H3N2 pre-immune mice

by Riley Nolan | Jun 16, 2022

Novel H7N9 influenza immunogen design enhances mobilization of seasonal influenza T cell memory in H3N2 pre-immune mice
A novel SARS-CoV-2 T cell targeting, peptide-based vaccine candidate designed using the iVAX platform

A novel SARS-CoV-2 T cell targeting, peptide-based vaccine candidate designed using the iVAX platform

by Riley Nolan | Jun 7, 2022

A novel SARS-CoV-2 T cell targeting, peptide-based vaccine candidate designed using the iVAX platform
Novel immunogen design elicits increased protection against avian H7N9 influenza that is associated with mobilization of seasonal influenza T cell memory

Novel immunogen design elicits increased protection against avian H7N9 influenza that is associated with mobilization of seasonal influenza T cell memory

by Riley Nolan | Sep 13, 2021

Novel immunogen design elicits increased protection against avian H7N9 influenza that is associated with mobilization of seasonal influenza T cell memory
« Older Entries

Recent Posts

  • From Kyoto, with Love
  • EpiVax Turns 25!
  • Happy Valentine’s Day! And don’t argue with Chatbots!
  • ISPRI in silico Toolkit in the Literature
  • Platform shoes, Bellbottoms and #CrueltyFreeFDA!

Categories

  • EpiVax Immunoncology
  • Events
  • Featured
  • News
  • Recipes for Success – Vlog
  • Thinking Out Loud -Blog
  • Uncategorized
  • Webinars

Discover

  • Vaccine Services
  • Immunogenicity Assessment
  • Deimmunization
  • Lab Services
  • Pipeline

About

  • Our Company
  • Press Room
  • Events
  • Publication & Poster Search
  • Thinking Out Loud (Blog)
  • Contact Us

Connect

© 2023 EpiVax, Inc. – Informatics and Immunology, All rights reserved. Privacy Policy • 188 Valley Street, Suite 424, Providence, RI 02909 • ph: 401.272.2123 • fax: 401.272.7562